Inhibition of TGFβ signaling in cancer therapy

Current Opinion in Genetics and Development

Volumn 16, Issue 1, 2006, Pages 30-37

  Arteaga, Carlos L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; AP 11014; AP 12009; DOXYCYCLINE FOSFATEX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GC 1008; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LERDELIMUMAB; LY 580276; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P85; RAC PROTEIN; RHO FACTOR; SB 505124; SD 093; SD 908; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL MOLECULE TRANSPORT AGENT; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; SMAD PROTEIN; TUMOR MARKER;

CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL MOTILITY; CELL SURVIVAL; CELL TRANSFORMATION; EPITHELIUM CELL; HUMAN; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE H RAS; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; MOUSE; NEOPLASM; ONCOGENE;

ANIMALS; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; ONCOGENES; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 30644467227     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2005.12.009     Document Type: Review

References (61)

1. A.B. Roberts, L.C. Lamb, D.L. Newton, M.B. Sporn, J.E. De Larco, and G.J. Todaro Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction Proc Natl Acad Sci USA 77 1980 3494 3498
2. H.L. Moses, E.L. Branum, J.A. Proper, and R.A. Robinson Transforming growth factor production by chemically transformed cells Cancer Res 41 1981 2842 2848
3. P.M. Siegel, and J. Massague Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer Nat Rev Cancer 3 2003 807 820
4. N. Dumont, and C.L. Arteaga Targeting the TGFβ signaling network in human neoplasia Cancer Cell 3 2003 531 536
5. F. Tian, S.D. Byfield, W.T. Parks, C.H. Stuelten, D. Nemani, Y.E. Zhang, and A.B. Roberts Smad-binding defective mutant of transforming growth factor β type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines Cancer Res 64 2004 4523 4530 The authors provide an excellent demonstration of the dual role of TGFβ in transformation. In an established model of breast epithelial transformation, abrogation of Smad signaling accelerates tumor formation but delays the metastatic progression of tumors.
6. P.M. Siegel, W. Shu, R.D. Cardiff, W.J. Muller, and J. Massague Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis Proc Natl Acad Sci USA 100 2003 8430 8435
7. R.S. Muraoka, Y. Koh, L.R. Roebuck, M.E. Sanders, D. Brantley-Sieders, A.E. Gorska, H.L. Moses, and C.L. Arteaga Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor β1 Mol Cell Biol 23 2003 8691 8703
8. R.S. Muraoka-Cook, H. Kurokawa, Y. Koh, J.T. Forbes, L.R. Roebuck, M.H. Barcellos-Hoff, S.E. Moody, L.A. Chodosh, and C.L. Arteaga Conditional overexpression of active transforming growth factor β1 in vivo accelerates metastases of transgenic mammary tumors Cancer Res 64 2004 9002 9011
9. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL: Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 2005, DOI:10.1038/sj.onc.1208964. One of the first demonstrations of TGFβ-mediated activation of the PI3K pathway in vivo. Expression of an active mutant of Alk5 in the mammary gland of transgenic mice enhanced PI3K-dependent epithelial cell survival and synergized with Neu in accelerating metastatic progression of Neu-induced mammary tumors.
10. M. Oft, R.J. Akhurst, and A. Balmain Metastasis is driven by sequential elevation of H-ras and Smad2 levels Nat Cell Biol 4 2002 487 494
11. E. Forrester, A. Chytil, B. Bierie, M. Aakre, A.E. Gorska, A.R. Sharif-Afshar, W.J. Muller, and H.L. Moses Effect of conditional knockout of the type II TGF-β receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis Cancer Res 65 2005 2296 2302
12. E. Ziv, J. Cauley, P.A. Morin, R. Saiz, and W.S. Browner Association between the T29C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women: the study of osteoporotic fractures JAMA 285 2001 2859 2863
13. A.M. Dunning, P.D. Ellis, S. McBride, H.L. Kirschenlohr, C.S. Healey, P.R. Kemp, R.N. Luben, J. Chang-Claude, A. Mannermaa, and V. Kataja A transforming growth factorβ1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer Cancer Res 63 2003 2610 2615
14. X.O. Shu, Y.T. Gao, Q. Cai, L. Pierce, H. Cai, Z.X. Ruan, G. Yang, F. Jin, and W. Zheng Genetic polymorphisms in the TGF-β 1 gene and breast cancer survival: a report from the Shanghai breast cancer study Cancer Res 64 2004 836 839
15. B. Pasche, V. Kaklamani, N. Hou, T. Young, A. Rademaker, P. Peterlongo, N. Ellis, K. Offit, T. Caldes, and M. Reiss TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies J Clin Oncol 22 2004 756 758
16. B. Pasche, T.J. Knobloch, Y. Bian, J. Liu, S. Phukan, D. Rosman, V. Kaklamani, L. Baddi, F.S. Siddiqui, and W. Frankel Somatic acquisition and signaling of TGFBR1*6A in cancer JAMA 294 2005 1634 1646 First demonstration of a somatically acquired polymorphism in the TGFBRI gene in colon, head and neck cancers. This polymorphism can bestow cancer cells with a growth advantage in the presence of TGFβ and represents a potential biomarker for the selection of patients into trials with TGFβ inhibitors.
17. T. Lu, L.G. Burdelya, S.M. Swiatkowski, A.D. Boiko, P.H. Howe, G.R. Stark, and A.V. Gudkov Secreted transforming growth factor β2 activates NFκB, blocks apoptosis, and is essential for the survival of some tumor cells Proc Natl Acad Sci USA 101 2004 7112 7117
18. J.Y. Yi, I. Shin, and C.L. Arteaga Type I transforming growth factor β receptor binds to and activates phosphatidylinositol 3-kinase J Biol Chem 280 2005 10870 10876
19. J.C. Horowitz, D.Y. Lee, M. Waghray, V.G. Keshamouni, P.E. Thomas, H. Zhang, Z. Cui, and V.J. Thannickal Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-β1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor J Biol Chem 279 2004 1359 1367
20. I. Shin, A.V. Bakin, U. Rodeck, A. Brunet, and C.L. Arteaga Transforming growth factor β enhances epithelial cell survival via Akt-dependent regulation of FKHRL1 Mol Biol Cell 12 2001 3328 3339
21. Y. Huang, D. Hutter, Y. Liu, X. Wang, M.S. Sheikh, A.M. Chan, and N.J. Holbrook Transforming growth factor-β 1 suppresses serum deprivation-induced death of A549 cells through differential effects on c-Jun and JNK activities J Biol Chem 275 2000 18234 18242
22. J. Gotzmann, H. Huber, C. Thallinger, M. Wolschek, B. Jansen, R. Schulte-Hermann, H. Beug, and W. Mikulits Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-β1 and Ha-Ras: steps towards invasiveness J Cell Sci 115 2002 1189 1202
23. J. Seoane, H.V. Le, L. Shen, S.A. Anderson, and J. Massague Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation Cell 117 2004 211 223 Elegant molecular demonstration of how PI3K, by modulation of Foxo transcription factors, attenuates the Smad-dependent anti-mitogenic effect of TGFβ on glioma cells.
24. A.R. Conery, Y. Cao, E.A. Thompson, C.M. Townsend Jr., T.C. Ko, and K. Luo Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β induced apoptosis Nat Cell Biol 6 2004 366 372
25. I. Remy, A. Montmarquette, and S.W. Michnick PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3 Nat Cell Biol 6 2004 358 365
26. A.L. Mead, T.T. Wong, M.F. Cordeiro, I.K. Anderson, and P.T. Khaw Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery Invest Ophthalmol Vis Sci 44 2003 3394 3401
27. R.S. Muraoka, N. Dumont, C.A. Ritter, T.C. Dugger, D.M. Brantley, J. Chen, E. Easterly, L.R. Roebuck, S. Ryan, and P.J. Gotwals Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases J Clin Invest 109 2002 1551 1559
28. A. Bandyopadhyay, F. Lopez-Casillas, S.N. Malik, J.L. Montiel, V. Mendoza, J. Yang, and L.Z. Sun Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft Cancer Res 62 2002 4690 4695
29. J.M. Yingling, K.L. Blanchard, and J.S. Sawyer Development of TGF-β signalling inhibitors for cancer therapy Nat Rev Drug Discov 3 2004 1011 1022 An up-to-date and outstanding review of the medicinal chemistry and status of the clinical development of TGFβ inhibitors in cancer.
30. G. Subramanian, R.E. Schwarz, L. Higgins, G. McEnroe, S. Chakravarty, S. Dugar, and M. Reiss Targeting endogenous transforming growth factor β receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1 Cancer Res 64 2004 5200 5211
31. S.B. Peng, L. Yan, X. Xia, S.A. Watkins, H.B. Brooks, D. Beight, D.K. Herron, M.L. Jones, J.W. Lampe, and W.T. McMillen Kinetic characterization of novel pyrazole tgf-β receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition Biochemistry 44 2005 2293 2304
32. S.K. Halder, R.D. Beauchamp, and P.K. Datta A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers Neoplasia 7 2005 509 521
33. M. Uhl, S. Aulwurm, J. Wischhusen, M. Weiler, J.Y. Ma, R. Almirez, R. Mangadu, Y.W. Liu, M. Platten, and U. Herrlinger SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo Cancer Res 64 2004 7954 7961
34. S. DaCosta Byfield, C. Major, N.J. Laping, and A.B. Roberts SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7 Mol Pharmacol 65 2004 744 752
35. G.J. Inman, F.J. Nicolas, J.F. Callahan, J.D. Harling, L.M. Gaster, A.D. Reith, N.J. Laping, and C.S. Hill SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 Mol Pharmacol 62 2002 65 74
36. B.C. Kim, H. van Gelder, T.A. Kim, H.J. Lee, K.G. Baik, H.H. Chun, D.A. Lee, K.S. Choi, and S.J. Kim Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells J Biol Chem 279 2004 28458 28465
37. M.D. Landis, D.D. Seachrist, M.E. Montanez-Wiscovich, D. Danielpour, and R.A. Keri Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-β signaling in ErbB2/Neu-induced tumors from transgenic mice Oncogene 24 2005 5173 5190
38. G. Xu, Y. Zhong, S. Munir, B.B. Yang, B.K. Tsang, and C. Peng Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7 J Clin Endocrinol Metab 89 2004 5523 5534
39. U. Bogdahn, P. Hau, A. Brawanski, J. Schlaier, M. Mehdorn, G. Wurm, J. Pichler, M. Kunst, G. Stauder, and K.-H. Schlingensiepen Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP12009 Proc Am Soc Clin Oncol 23 2004 110
40. K-H. Schlingensiepen, A. Bischof, T. Egger, M. Hafner, H. Herrmuth, P. Jachimczak, M. Kielmanowicz, M. Niewel, E. Zavadova, and G. Stauder The TGF-β1 antisense oligonucleotide AP 11014 for the treatment of non-small-cell lung, colorectal and prostate cancer: preclinical studies Proc Am Soc Clin Oncol 23 2004 227
41. M.M. Shull, I. Ormsby, A.B. Kier, S. Pawlowski, R.J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, and D. Calvin Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease Nature 359 1992 693 699
42. Y.A. Yang, O. Dukhanina, B. Tang, M. Mamura, J.J. Letterio, J. MacGregor, S.C. Patel, S. Khozin, Z.Y. Liu, and J. Green Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects J Clin Invest 109 2002 1607 1615
43. D. Siriwardena, P.T. Khaw, A.J. King, M.L. Donaldson, B.M. Overton, C. Migdal, and M.F. Cordeiro Human antitransforming growth factor beta(2) monoclonal antibody-a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study Ophthalmology 109 2002 427 431
44. N. Dumont, A.V. Bakin, and C.L. Arteaga Autocrine transforming growth factor-β Signaling mediates smad- independent motility in human cancer cells J Biol Chem 278 2003 3275 3285
45. N.A. Bhowmick, M. Ghiassi, A. Bakin, M. Aakre, C.A. Lundquist, M.E. Engel, C.L. Arteaga, and H.L. Moses Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism Mol Biol Cell 12 2001 27 36
46. G. Han, S.L. Lu, A.G. Li, W. He, C.L. Corless, M. Kulesz-Martin, and X.J. Wang Distinct mechanisms of TGF-β1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis J Clin Invest 115 2005 1714 1723 Expression of dominant-negative truncated TβRII and TGFβ in transgenic skin cancers accelerates tumor formation and metastases. These metastases did not exhibit molecular evidence of EMT. This study suggests that attenuated TGFβ-signaling cooperates with high levels of TGFβ ligand in tumor progression.
47. J. Kleeff, T. Ishiwata, H. Maruyama, H. Friess, P. Truong, M.W. Buchler, D. Falb, and M. Korc The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer Oncogene 18 1999 5363 5372
48. M. Iglesias, P. Frontelo, C. Gamallo, and M. Quintanilla Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas Oncogene 19 2000 4134 4145
49. T. Watanabe, T.T. Wu, P.J. Catalano, T. Ueki, R. Satriano, D.G. Haller, A.B. Benson III, and S.R. Hamilton Molecular predictors of survival after adjuvant chemotherapy for colon cancer N Engl J Med 344 2001 1196 1206
50. M. Wagner, J. Kleeff, H. Friess, M.W. Buchler, and M. Korc Enhanced expression of the type II transforming growth factor-β receptor is associated with decreased survival in human pancreatic cancer Pancreas 19 1999 370 376
51. M. Tateishi, I. Kusaba, H. Masuda, T. Tanaka, T. Matsumata, and K. Sugimachi The progression of invasiveness regarding the role of transforming growth factor β receptor type II in gastric cancer Eur J Surg Oncol 26 2000 377 380
52. P. Liu, K. Menon, E. Alvarez, K. Lu, and B.A. Teicher Transforming growth factor-β and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo Int J Oncol 16 2000 599 610
53. B.A. Teicher, Y. Kakeji, G. Ara, R.S. Herbst, and D. Northey Prostate carcinoma response to cytotoxic therapy: in vivo resistance In Vivo 11 1997 453 461
54. B.A. Teicher, M. Ikebe, G. Ara, S.R. Keyes, and R.S. Herbst Transforming growth factor-β 1 overexpression produces drug resistance in vivo: reversal by dEcoRIn In Vivo 11 1997 463 472
55. E. Janda, K. Lehmann, I. Killisch, M. Jechlinger, M. Herzig, J. Downward, H. Beug, and S. Grunert Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways J Cell Biol 156 2002 299 313
56. D. Saha, P.K. Datta, and R.D. Beauchamp Oncogenic ras represses transforming growth factor-β/Smad signaling by degrading tumor suppressor Smad4 J Biol Chem 276 2001 29531 29537
57. K.M. Mulder Role of Ras and Mapks in TGFβ signaling Cytokine Growth Factor Rev 11 2000 23 35
58. -/- tumors in vivo. This result suggests an important role for autocrine TGFβ signaling in oncogene-induced tumor progression.
59. S.E. Seton-Rogers, Y. Lu, L.M. Hines, M. Koundinya, J. LaBaer, S.K. Muthuswamy, and J.S. Brugge Cooperation of the ErbB2 receptor and transforming growth factor β in induction of migration and invasion in mammary epithelial cells Proc Natl Acad Sci USA 101 2004 1257 1262
60. Y. Ueda, S. Wang, N. Dumont, J.Y. Yi, Y. Koh, and C.L. Arteaga Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor β-induced cell motility J Biol Chem 279 2004 24505 24513
61. Y. Kang, W. He, S. Tulley, G.P. Gupta, I. Serganova, C.R. Chen, K. Manova-Todorova, R. Blasberg, W.L. Gerald, and J. Massague Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway Proc Nat Acad Sci USA 102 2005 13909 13914